Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease.
Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease.
复制标题
DOI：
10.31531/2581-4745.1000106
复制
发表时间：
2018-01-01
期刊：
影响因子：
--
通讯作者：
D, Lopez
中科院分区：
文献类型：
--
作者：
Ce, Oldham;Rs, Powell;D, Lopez
阿尔茨海默病（Alzheimer's disease，AD）是最常见的神经退行性疾病，目前仍无法治愈。前蛋白转化酶枯草杆菌蛋白酶/kexin-9 [PCSK 9]是控制质膜LDL受体表达的血浆低密度脂蛋白[LDL]水平的间接调节剂。PCSK 9似乎还调节葡萄糖耐受不良、胰岛素抵抗、腹部肥胖、炎症和高血压的发展，这些疾病已被确定为AD的风险因素。PCSK 9水平还取决于年龄、性别和种族背景，这些因素与AD相关。在此，我们将回顾表明PCSK 9水平与AD之间存在联系的间接证据。
Alzheimer's disease [AD] is not only the most common neurodegenerative disease but is also currently incurable. Proprotein convertase subtilisin/kexin-9 [PCSK9] is an indirect regulator of plasma low density lipoprotein [LDL] levels controlling LDL receptor expression at the plasma membrane. PCSK9 also appears to regulate the development of glucose intolerance, insulin resistance, abdominal obesity, inflammation, and hypertension, conditions that have been identified as risk factors for AD. PCSK9 levels also depend on age, sex, and ethnic background, factors associated with AD. Herein, we will review indirect evidence that suggests a link between PCSK9 levels and AD.